Mortality and potential years of life lost attributable to non-optimal glycaemic control in men and women with diabetes in the United Arab Emirates: a population-based retrospective cohort study

Saif Al-Shamsi, 1 Romona Devi Govender, 2 Elpidoforos S Soteriades 3

ABSTRACT

Objectives Numerous studies reported that achieving near-normal glycated haemoglobin (HbA1c) levels in patients with diabetes may delay or even prevent vascular complications. However, information regarding the impact of non-optimal HbA1c control on adverse health outcomes in an Arab population is unknown. The aim of this study was to estimate the fraction of deaths and potential years of life lost (PYLL) attributable to non-optimal HbA1c control among Emiratni men and women with diabetes in the United Arab Emirates (UAE).

Design A retrospective cohort study.

Setting This study was conducted in outpatient clinics at a tertiary care centre in Al Ain, UAE, between April 2008 and September 2018.

Participants The sample comprised of 583 adult UAE nationals, aged $\geq$ 18 years, with diabetes. Overall, 57% (n=332) of the study participants were men and 43% (n=251) were women.

Exposure Non-optimal HbA1c control, defined as HbA1c $\geq$ 6.5%.

Primary outcome measure All-cause mortality, defined as death from any cause.

Results At the end of the 9-year follow-up period, 86 (14.8%) participants died. Overall, up to 33% (95% CI 2% to 63%) of deaths were attributable to non-optimal HbA1c control among patients with diabetes mellitus (DM). Stratified by sex, the adjusted fraction of avoidable mortality was 17% (95% CI –23% to 57%) for men and 50% (95% CI 3% to 98%) for women. Both deaths and PYLL attributable to non-optimal HbA1c control were higher in women compared with men.

Conclusions Up to one-third of all deaths in adult UAE nationals with DM could be attributed to non-optimal HbA1c control. Effective sex-specific interventions and healthcare quality-improvement programmes should urgently be implemented.

INTRODUCTION

The WHO estimates that type 2 diabetes mellitus (DM) was the seventh leading cause of death worldwide in 2016. 1 The global prevalence of DM among adults has more than doubled over the past four decades and continues to rise. 1

The United Arab Emirates (UAE) has witnessed substantial economic development since the discovery of oil half a century ago. This increased prosperity has altered the health profile in the UAE with improved access to modern healthcare services and universal health insurance for its citizens. 2 In the UAE, life expectancy at birth is slowly improving and the most recent estimates for men and women were 76.4 and 80.2 years, respectively, in 2017. 3 However, this dramatic economic transformation has also led to major lifestyle changes among its residents. Sedentary lifestyles and unhealthy dietary
habs have resulted in the UAE having one of the highest prevalence of DM worldwide with an age-adjusted prevalence of 17.3% in 2017.1

DM substantially increases the risk of cardiovascular disease (CVD), renal disease, visual impairment and peripheral neuropathy,5-7 as well as the risk of premature death.8 The WHO estimates that around half of all global deaths in patients with DM aged under 70 years are attributable to poor glycaemic control,1 while the proportion of all deaths due to DM among UAE residents aged under 60 years was 69.1%.4

There is strong evidence that achieving near-normal glycated haemoglobin (HbA1c) levels in DM significantly reduces morbidity and mortality.9 However, despite this evidence, less than half of patients with DM achieve their HbA1c target. A UAE study, in 2015, reported that only 38% of adult patients with DM had achieved the HbA1c target of <7% and that poor glycaemic control was higher in females and patients aged >60 years.10 This result was similar to a US study, conducted more than a decade ago, which reported that only 34% of patients with DM had achieved optimal glycaemic control.11

The proportion of deaths avoided if patients had achieved the HbA1c target can be quantified by measuring the impact of a specific risk factor on public health, and is described as the population- attributable fraction (PAF).12 Since no evidence exists regarding the impact of non-optimal HbA1c control on mortality among Arab patients with diabetes, the aim of this study was to estimate the fraction of deaths and potential years of life lost (PYLL) attributable to non-optimal HbA1c control in UAE nationals with DM.

METHODOLOGY

This was a retrospective cohort study based on data obtained from electronic medical records of UAE nationals with DM, registered at outpatient clinics at Tawam Hospital in Al Ain, UAE, between 01 April 2008 and 31 December 2008. Tawam Hospital is a tertiary care hospital, which provides healthcare services to approximately 19000 adult UAE nationals with DM of Al Ain, the second-largest city in the Emirate of Abu Dhabi, UAE. We included consecutive patients aged ≥18 years who had serum HbA1c level ≥6.5%, a diagnosis established by a physician or been receiving medications for DM (eg, sulfonylurea, thiazolidinedione, dipeptidyl peptidase-4 inhibitor, biguanide or insulin). Patients with incomplete data on serum HbA1c levels and missing history of DM at baseline were excluded (figure 1). Annual follow-up data were obtained between the baseline visits in 2008 and 30 September 2018.

**Definitions of clinical variables and outcomes**

Hypertension (HTN) was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg or the use of antihypertensive medications.13 Fasting lipid profiles were measured using standard methods and the UniCel Dxc-800 Synchron Clinical System (Beckman Coulter, Brea, California, USA). Dyslipidaemia was defined as the presence of one or more of the following: triglyceride ≥1.69 mmol/L, total cholesterol ≥5.17 mmol/L, low-density lipoprotein cholesterol ≥3.36 mmol/L, high-density lipoprotein cholesterol <1.03 mmol/L or documented treatment with lipid-lowering medications.14 Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared and obesity was defined as BMI ≥30 kg/m². Smoking history was positive if there was a current or history of smoking of tobacco. Patients were considered as having CVD if they had a diagnosis of coronary heart disease (angina, prior myocardial infarction, angioplasty of the coronary arteries or coronary artery surgery), cerebrovascular accidents or peripheral vascular disease. History of cancer was defined as an established diagnosis of cancer of any type. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate <60 mL/min/1.73 m².15 HbA1c was assessed by the medical laboratory department at Tawam Hospital using an automated analyser (Integra 400 Plus; Roche Diagnostics GmbH, Mannheim, Germany). Non-optimal HbA1c control was defined as HbA1c ≥6.5%.16

Mortality data were collected retrospectively during the follow-up period until 30 September 2018. Death was defined as death from any cause and was confirmed through the review of medical records and death certificates. Time to event was calculated for each patient as the difference between the date of the inclusion into the study and the date of death, or the date of the last outpatient clinic visit, whichever occurred first.

**Statistical analysis**

Data were expressed as mean±SD or percentages. The baseline characteristics were compared by sex using the
Table 1 Baseline characteristics of study participants by sex

| Characteristic          | Total (n=583) | Women (n=251) | Men (n=332) | P value* |
|-------------------------|---------------|---------------|-------------|----------|
| Age (years), mean±SD    | 58.4±12.4     | 57.0±11.4     | 59.4±13.0   | 0.021    |
| Age (years), n (%)      |               |               |             |          |
| ≤39                     | 50 (8.6)      | 18 (7.2)      | 32 (9.6)    | <0.001   |
| 40–54                   | 155 (26.6)    | 88 (35.1)     | 67 (20.2)   |          |
| 55–64                   | 179 (30.7)    | 77 (30.7)     | 102 (30.7)  |          |
| ≥65                     | 199 (34.1)    | 68 (27.1)     | 131 (39.5)  |          |
| Women, n (%)            | 251 (43.1)    |               |             |          |
| DM medications, n (%)   | 487 (83.5)    | 202 (80.5)    | 285 (85.8)  | 0.091    |
| HbA1c (%), mean±SD      | 7.85±1.93     | 7.53±1.75     | 8.09±2.02   | <0.001   |
| HbA1c≥6.5%, n (%)       | 470 (80.6)    | 195 (77.7)    | 275 (82.8)  | 0.138    |
| Comorbidities, n (%)    |               |               |             |          |
| Smoking history         | 108 (18.5)    | 2 (0.8)       | 106 (31.9)  | <0.001   |
| Obesity†                | 276 (47.3)    | 151 (60.4)    | 125 (37.7)  | <0.001   |
| HTN                     | 495 (84.9)    | 209 (83.3)    | 286 (86.1)  | 0.352    |
| Dyslipidaemia           | 534 (91.6)    | 219 (87.3)    | 315 (94.9)  | 0.001    |
| CVD                     | 150 (25.7)    | 33 (13.1)     | 117 (35.2)  | <0.001   |
| Cancer                  | 46 (7.9)      | 21 (8.4)      | 25 (7.5)    | 0.757    |
| CKD                     | 89 (15.3)     | 31 (12.4)     | 58 (17.5)   | 0.103    |

*The independent samples t-test was used to calculate p values for continuous variables, and Fisher’s exact test (two-tailed) was used to calculate p values for categorical variables.

†n=582.

CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; HbA1c, glycated haemoglobin; HTN, hypertension.
men than in women (p<0.001). There were no significant differences by sex in non-optimal HbA1c control at baseline (p=0.138).

**Mortality and PYLL**

At the end of the follow-up period, 86 (14.8%) deaths occurred. The multivariable-adjusted HR for all-cause mortality comparing patients with and without optimal HbA1c control was 1.79 (95% CI 0.95 to 3.39). The multivariable-adjusted PAF for deaths due to non-optimal HbA1c control was 33% (95% CI 2% to 63%) (table 2).

Overall, 28 (95% CI 2 to 54) deaths could have been prevented if the HbA1c of all participants in the study had been maintained in the optimal range. Similarly, 190 (95% CI 12 to 363) PYLL could have been prevented if the HbA1c was optimal in all patients.

When stratified by sex, the confounder-adjusted fraction of avoidable mortality was 17% (95% CI 1% to 57%) for men and 50% (95% CI 3% to 98%) for women. Shown in figures 2 and 3, respectively, are the deaths and PYLL attributable to non-optimal HbA1c control, by age category and sex. The avertable deaths were higher for the older age groups in both men and women. In women, the avertable PYLL was higher in the 40–54 years age group; however, in men, the PYLL was higher in the 55–64 years age group. Overall, both deaths and PYLL attributable to non-optimal HbA1c control were higher in women than in men.

Extrapolating from our cohort to the approximately 155,000 adult UAE nationals with DM and assuming that this population is comparable to our study population, based on our results, we estimated that approximately 22,900 deaths would have been observed within 9 years among the Emirati population with DM. Of these total deaths, around 7,600 deaths would be attributable to non-optimal HbA1c control.

**DISCUSSION**

This long-term observational cohort study suggests that among adult Emiratis with DM, about one-third of all deaths over the 9-year period could have been prevented with optimal HbA1c control. By extrapolating our results to the UAE national population with DM, we estimated the burden of non-optimal HbA1c control among Emiratis. In the approximately 155,000 adult UAE nationals with DM, this would correspond to about 840 deaths that could have potentially been avoided annually.

There is only one comparable longitudinal study in the international literature that estimated the attributable risk associated with HbA1c levels for all-cause mortality in patients with DM. The cardiometabolic Valencian (ESCARVAL-RISK) study conducted on a large general-practice cohort of Spanish patients with DM reported the PAF associated with uncontrolled diabetes as 13.6% (95% CI 4.0% to 23.9%) for all-cause mortality. This estimate was much lower than what was observed in our study. This difference may be explained by different population characteristics and follow-up time between the two studies (patients with CVD were excluded from the ESCARVAL-RISK study and had a follow-up of 3.3
years vs 26% with a history of CVD and a follow-up of 9.1 years in our study).

To the best of our knowledge, the PAF linked to non-optimal HbA1c control by sex has not been previously reported. We found that more deaths could have been avoided in women with non-optimal HbA1c control than in men. Moreover, in our study, the PAF associated with uncontrolled diabetes was not statistically significantly contributing to the risk of mortality in men. Most previous studies have supported the claim that women with DM are at higher risk for morbidity and mortality compared with men with DM. A meta-analyses of patients with DM reported that women were 50% more likely to die of fatal coronary heart disease than men. It is not known why women with DM are at increased risk for morbidity and mortality compared with their male counterparts. One explanation is that CVD risk factors affect women more than men. The Strong Heart Study showed that between women with and without DM, the differences in levels of several CVD risk factors were greater than differences found in men with and without DM. Another possible explanation is that women with diabetes are less likely than men to have CVD risk factors aggressively treated. In addition, results from a Korean study on patients with DM showed that compared with men, women were less likely to achieve optimal HbA1c control after 1 year of treatment. Our findings demonstrate possible sex differences in mortality among Emirati patients with poorly controlled DM and support the urgent need for developing sex-specific tertiary prevention strategies in the UAE.

In our study, patients with DM had a moderate glycaemic control with a mean±SD HbA1c of 7.85%±1.93% at baseline and only approximately 19% of them had optimal HbA1c target of <6.5%. These results are consistent with other studies carried out in neighbouring Middle Eastern and Western countries, indicating that poor glycaemic control in patients with DM is a serious issue worldwide. A study conducted among 651 patients with DM in Saudi Arabia showed that close to 21% of patients had optimal HbA1c control. A nationwide French survey on 4930 patients with DM reported that the mean HbA1c was 7.6%±1.6% and in 27% of patients, the HbA1c level was ≤6.5%. Possible reasons for this failure may be multifactorial, such as poor compliance with medications, and therapeutic inertia on the part of healthcare providers. A recently published systematic review reported that the delay in the intensification of therapy following an HbA1c measurement above the target level was longer than 1 year. Furthermore, the increasing prevalence of multimorbidity among patients often complicates the management of DM, and may also contribute to suboptimal diabetes management. It is well-known and widely accepted that achieving optimal HbA1c target levels in patients with DM, as outlined in current clinical guidelines, decreases the risk of vascular complications and improves the life expectancy. Therefore, future studies, to investigate effective and efficient solutions in improving glycaemic control in patients with DM, should be high on the list of priorities for all decision-makers involved in DM care.

Strengths and limitations
To the best of our knowledge, this is the first long-term observational cohort study to estimate the fraction of deaths and PYLL attributable to non-optimal HbA1c control in UAE national men and women with DM. The PAF assesses potential health benefits through risk factor control and disease prevention. It is a helpful instrument for effective health communication that may increase both public and healthcare professionals’ awareness of DM. It may also aid in decreasing the risk of mortality with the implementation of healthcare quality-improvement programmes by key stakeholders.

This study has several limitations. First, the DM status was determined at baseline and could have changed during the follow-up period, which might have impacted our estimate of the PAF. However, transitions from diabetes to non-diabetes status are rare. Second, this study was conducted in outpatient clinics of a single tertiary care hospital; therefore, our results may not be applicable to the general population in the UAE. Third, the changes in HbA1c levels and DM treatment over time were not assessed and could have affected the study results. In addition, data on other confounding variables that could have impacted the study outcomes, such as the socioeconomic status, dietary habits and physical activity, were unavailable. Finally, the CIs for the PAF were wide, indicating that the sample size was relatively small; however, our study in an Arab population with a long follow-up duration gives us a better picture of the high burden of diabetes in the Middle East, where data on associated poor glycaemic control is sparse. Additional large multicenter studies are needed to confirm our results.

CONCLUSION
In conclusion, non-optimal HbA1c control contributed to one-third of all deaths in patients with DM in the UAE. This places a significant burden on the health of Emiratis with DM, their families and the health systems. Effective interventions, such as the training of DM care teams on sex-specific prevention strategies, periodic monitoring of DM and improving patients’ education, are essential to increase adherence to management guidelines and should be implemented without delay.

Author affiliations
1Internal Medicine, United Arab Emirates University College of Medicine and Health Sciences, Al Ain, United Arab Emirates
2Family Medicine, United Arab Emirates University College of Medicine and Health Sciences, Al Ain, United Arab Emirates
3Institute of Public Health, United Arab Emirates University College of Medicine and Health Sciences, Al Ain, United Arab Emirates

Contributors SAS, RDG and ESS contributed to the research idea and design of the study. SAS and RDG contributed to acquisition of data. SAS, RDG and ESS contributed to analysis and interpretation of data, and SAS was responsible for the
statistical analysis. SAS drafted the manuscript. SAS, RDG and ESS contributed to the critical revision of the manuscript for important intellectual content. All the authors have read and approved the final version of the manuscript.

**Funding** This work was supported by the College of Medicine and Health Sciences, UAE University (grant number 31M325).

**Disclaimer** The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** Ethical approval for this study was obtained from Tawam Hospital and the UAE University’s Research and Ethics Board (CRD 239/13).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open-access repository. Supplementary data and analysis can be accessed from the Mendeley repository [http://dx.doi.org/10.17632/n9j4ydmtnx.1]. All data have been provided in the study and anyone is permitted to use the data provided that the article is properly cited.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited.

**References**

1. Roglic G. WHO global report on diabetes: a summary. *Int J Noncommun Dis* 2016;1:3–8.
2. Koornneef E, Robben P, Blair I. Progress and outcomes of health systems reform in the United Arab Emirates: a systematic review. *BMJ Health Serv Res* 2017;17:672.
3. Statistics Centre – Abu Dhabi. Statistical Yearbook of abu dhabi, 2018. Available: https://www.scad.gov.abudhabi/Release%20Documents/SYB_2018_EN_Ne%20%20Char%20Correction.pdf [Accessed 18 Mar 2019].
4. International Diabetes Federation. *IDF diabetes atlas*. 8th ed. Brussels, Belgium: International Diabetes Federation, 2017.
5. Bourne RRA, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. *Lancet Glob Health* 2013;1:e339–49.
6. Sarwar N, Gaziano J, Halkjaer J, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010;375:2215–22.
7. Saran R, Li Y, Robinson B, et al. US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. *American Journal of Kidney Diseases* 2015;66:A7–305.
8. Saydah SH, Eberhardt MS, Loría CM, et al. Age and the burden of death attributable to diabetes in the United States. *Am J Epidemiol* 2002;156:714–9.
9. Rayshani A, Rawshani A, Frånzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2018;379:633–44.
10. Ali Malik A. Clinical diabetes care of patients with type 2 diabetes at a major tertiary care hospital in the United Arab Emirates. *J Diabetes Metab Disord Control* 2015;2.
11. Grant RW, Buse JB, Meigs JB, et al. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. *Diabetes Care* 2005;28:337–42.
12. Speigelman D, Hertzmark E, Wand HC, Point and interval estimates of partial population attributable risks in cohort studies: examples and software. *Cancer Causes Control* 2007;18:571–9.
13. National High Blood Pressure Education Program. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Bethesda (MD): National heart, lung, and blood Institute (US), 2004. Available: http://www.nchll.nlm.nih.gov/books/NBK9630 [Accessed 18 Mar 2019].
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA* 2001;285:2486–97.
15. Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. *KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl* 2013;1:150–.
16. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2019. *Diabetes Care* 2019;42(Suppl 1):S61–S70.
17. Dahloqvist E, Zetterqvist J, Pawitn Y, et al. Model-Based estimation of the attributable fraction for cross-sectional, case-control and cohort studies using the R package AF. *Eur J Epidemiol* 2016;31:575–82.
18. Nooreño-Pérez JJ, Orozco-Beltran D, Gil-Guillen V, et al. Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study. *BMC Cardiovasc Disord* 2018;18:180.
19. Barnett KN, Ogston SA, McMurdo MET, et al. A 12-year follow-up study of all-cause and cardiovascular mortality in 10,532 people newly diagnosed with type 2 diabetes in Tayside, Scotland. *Diabet Med* 2010;27:1124–9.
20. Natarajan S, Liao Y, Cao G, et al. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. *Arch Intern Med* 2003;163:1735–40.
21. Juutilainen A, Kortelainen S, Lehto S, et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. *Diabetes Care* 2004;27:988–904.
22. Roche MM, Wang PP. Sex differences in all-cause and cardiovascular mortality, diabetes, and hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late. *Diabetes Care* 2013;36:2582–90.
23. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. *BMJ* 2006;332:73–8.
24. Howard BV, Cowan LD, Go O, et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The strong heart study. *Diabetes Care* 1998;21:1259–65.
25. Gouni-Berthold I, Berthold HK, Mantzoros CS, et al. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. *Diabetes Care* 2008;31:1389–91.
26. Choe S-A, Kim JY, Ro YS, et al. Women are less likely than men to achieve optimal glycemic control after 1 year of treatment: a multi-level analysis of a Korean primary care cohort. *PLOS One* 2018;13:e0196719.
27. Al-Hussein FA. Diabetes control in a primary care setting: a retrospective study of 651 patients. *Ann Saudi Med* 2004;28:267–71.
28. Rätsep A, Kaldal R, Lamberg M. Meeting targets in type 2 diabetes care contributing to good glycaemic control. A cross-sectional study from a primary care setting in Estonia. *Eur J Gen Pract* 2010;16:85–91.
29. Charpentier G, Genèès N, Vaur L, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. *Diabetes Metab* 2003;29:152–8.
30. Alvarez Guisasola F, Navros P, Nocosa G, et al. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. *Diabetes Obes Metab* 2008;10 Suppl 1:8–15.
31. Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. *Diabetes Obes Metab* 2018;20:427–37.
32. Magnan EM, Palta MA, Mahoney JE, et al. The relationship of individual comorbid chronic conditions to diabetes care quality. *BMJ Open Diabetes Res Care* 2015;5:e000080.
33. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. *Diabetes Res Clin Pract* 2014;104:1–52.
34. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. *Diabetes Care* 2015;38:140–9.
35. Karter AJ, Nundy S, Parker MM, et al. Incidence of remission in adults with type 2 diabetes: the diabetes & aging study. *Diabetes Care* 2014;37:3188–95.

BMJ Open: first published as 10.1136/bmjopen-2019-032654 on 8 September 2019. Downloaded from http://bmjopen.bmj.com on September 18, 2023 by guest. Protected by copyright.